The promise of a six-month HIV injection is simple: one jab, half a year of protection. For a country like South Africa, where daily pill adherence remains a persistent hurdle, the rollout of lenacapavir represents a potential turning point. But the infrastructure required to deliver this life-saving technology is fraying.

Last year, the US President’s Emergency Plan for Aids Relief (PEPFAR) pulled funding from a network of specialized clinics. These sites were designed for "key populations"—men who have sex with men, sex workers, and transgender individuals—who face disproportionate HIV risk and, often, profound stigma in the public sector. Now, as the government begins distributing lenacapavir, those specialized safety nets are gone.

The Cost of Stigma

For many, the public hospital is not a place of healing. It is a place of judgment. Keegan Daniels, a 29-year-old gay man, learned this the hard way when he sought oral PrEP at a public clinic. Instead of a routine consultation, he was met with moralizing lectures about his sexual orientation and the "abnormality" of his lifestyle.

This is not an isolated anecdote. It is a structural failure. When patients feel shamed, they stop coming back. They stop taking their medication. They drop out of the system entirely.

Specialized clinics were the antidote to this culture. They provided a space where patients could be honest about their lives without fear of being reprimanded. By closing these doors, the health system has effectively pushed the most vulnerable patients back into the very environments that drove them away in the first place.

Why the Timing Matters

South Africa is home to the world’s largest PrEP program, with over 2.1 million initiations to date. Yet, uptake has consistently lagged behind targets. The program gained real momentum only after PEPFAR began funding initiatives specifically tailored to key populations.

Now, that support has evaporated. The timing could not be worse. Lenacapavir requires a clinical environment that is both accessible and non-judgmental. If the delivery mechanism is broken, the drug’s efficacy in the real world will suffer.

The Challenge of Delivery

Injectable PrEP is not just a different drug; it is a different delivery model. It requires consistent follow-up visits every six months. If a patient feels unwelcome at their local clinic, they will miss that second appointment.

"PrEP is central to South Africa’s HIV response because treatment alone will not end the epidemic," says Foster Mohale, spokesperson for the national department of health. He is right. But a drug is only as good as the system that delivers it.

Key Takeaways

  • Infrastructure Gap: The closure of PEPFAR-funded specialized clinics has removed safe spaces for key populations to access HIV prevention services.
  • Stigma as a Barrier: Discrimination in public hospitals remains a primary driver of low PrEP uptake among men who have sex with men and other high-risk groups.
  • The Injection Challenge: Lenacapavir’s success depends on long-term retention, which is difficult to achieve in environments where patients feel judged or unwelcome.

What Experts Say

Mitchell Warren, executive director of the advocacy group AVAC, notes that while South Africa has built a massive program, it has not yet delivered the impact the country needs. The loss of specialized delivery initiatives threatens to widen that gap. Without a concerted effort to rebuild these specialized services, the rollout of lenacapavir risks becoming a technological success that fails to reach the people who need it most.

The government’s next quarterly report on PrEP uptake will be the first real test of this new reality. By then, the data will show whether the shift to general public clinics has deterred patients or if the convenience of a six-month injection is enough to overcome the shadow of stigma. The window to adjust the strategy is closing.